Q1 Earnings Estimate for OTLK Issued By HC Wainwright

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Outlook Therapeutics in a research report issued on Tuesday, February 18th. HC Wainwright analyst D. Tsao expects that the company will post earnings of ($0.21) per share for the quarter. HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($2.25) per share. HC Wainwright also issued estimates for Outlook Therapeutics’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.16) EPS and FY2029 earnings at $3.24 EPS.

Outlook Therapeutics (NASDAQ:OTLK) last released its quarterly earnings data on Friday, February 14th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.04).

OTLK has been the subject of several other research reports. BTIG Research lowered their price objective on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 29th. Guggenheim reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Outlook Therapeutics in a research note on Friday, January 17th. Finally, Chardan Capital reissued a “neutral” rating and set a $3.00 target price on shares of Outlook Therapeutics in a research report on Tuesday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

Outlook Therapeutics Stock Down 8.6 %

Outlook Therapeutics stock opened at $1.71 on Wednesday. The business has a 50 day moving average of $1.88 and a 200-day moving average of $4.41. Outlook Therapeutics has a 1 year low of $0.87 and a 1 year high of $12.85.

Hedge Funds Weigh In On Outlook Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of OTLK. Rhumbline Advisers boosted its holdings in shares of Outlook Therapeutics by 1,329.6% during the 4th quarter. Rhumbline Advisers now owns 188,050 shares of the company’s stock worth $355,000 after buying an additional 174,896 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Outlook Therapeutics during the 4th quarter worth approximately $246,000. Geode Capital Management LLC boosted its holdings in shares of Outlook Therapeutics by 49.2% during the 3rd quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock worth $1,826,000 after buying an additional 112,812 shares in the last quarter. Scotia Capital Inc. boosted its holdings in shares of Outlook Therapeutics by 124.4% during the 4th quarter. Scotia Capital Inc. now owns 73,989 shares of the company’s stock worth $140,000 after buying an additional 41,023 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Outlook Therapeutics during the 3rd quarter worth approximately $199,000. 11.20% of the stock is currently owned by institutional investors.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.